Ieq Capital LLC Has $274,000 Stock Position in Kenvue Inc. (NYSE:KVUE)

Ieq Capital LLC lifted its stake in shares of Kenvue Inc. (NYSE:KVUE) by 20.0% in the 4th quarter, Holdings Channel reports. The institutional investor owned 12,853 shares of the company’s stock after purchasing an additional 2,146 shares during the quarter. Ieq Capital LLC’s holdings in Kenvue were worth $274,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of KVUE. State Street Corp grew its holdings in Kenvue by 16.8% during the 3rd quarter. State Street Corp now owns 127,213,940 shares of the company’s stock worth $2,942,458,000 after acquiring an additional 18,283,473 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in shares of Kenvue by 8.9% during the third quarter. Massachusetts Financial Services Co. MA now owns 86,979,341 shares of the company’s stock worth $2,011,832,000 after purchasing an additional 7,115,374 shares during the period. Holocene Advisors LP grew its stake in shares of Kenvue by 75.5% in the third quarter. Holocene Advisors LP now owns 13,886,454 shares of the company’s stock worth $321,194,000 after purchasing an additional 5,975,392 shares during the last quarter. M&G PLC increased its holdings in Kenvue by 538.0% in the third quarter. M&G PLC now owns 4,341,172 shares of the company’s stock valued at $99,847,000 after purchasing an additional 3,660,730 shares during the period. Finally, FMR LLC raised its position in Kenvue by 2.3% during the 3rd quarter. FMR LLC now owns 137,915,493 shares of the company’s stock worth $3,189,985,000 after purchasing an additional 3,075,019 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Kenvue Stock Performance

Shares of Kenvue stock opened at $23.58 on Friday. The business has a 50-day simple moving average of $21.46 and a 200 day simple moving average of $22.26. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The firm has a market capitalization of $45.07 billion, a price-to-earnings ratio of 44.49, a PEG ratio of 2.62 and a beta of 1.45.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, research analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were issued a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.48%. The ex-dividend date was Wednesday, February 12th. Kenvue’s dividend payout ratio is currently 154.72%.

Analysts Set New Price Targets

A number of equities research analysts have commented on KVUE shares. Canaccord Genuity Group reduced their price target on Kenvue from $27.00 to $24.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Citigroup decreased their target price on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research report on Wednesday, January 15th. Royal Bank of Canada restated a “sector perform” rating and issued a $24.00 price target on shares of Kenvue in a research report on Monday, February 3rd. UBS Group decreased their price objective on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research report on Friday, February 7th. Finally, Piper Sandler boosted their target price on shares of Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a report on Monday, February 24th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $23.08.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.